Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 10/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281258 | 0.85 | EPHX1 (0.41) | PSMB5MAPK14EPHX1PSMB8 | |
| SCHEMBL2281260 | 0.85 | EPHX1 (0.41) | PSMB5MAPK14EPHX1PSMB8 | |
| SCHEMBL12374502 | 0.83 | PSMB5 (0.41) | PSMB5CACNA1BEPHX1PSMB8MEN1 | |
| SCHEMBL2283112 | 0.83 | PSMB5 (0.41) | PSMB5CACNA1BEPHX1PSMB8MEN1 | |
| SCHEMBL2283105 | 0.83 | PSMB5 (0.41) | PSMB5CACNA1BEPHX1PSMB8MEN1 | |
| SCHEMBL1147395 | 0.82 | EPHX1 (0.44) | PSMB5EPHX1PSMB8MEN1KMT2A | |
| SCHEMBL1411201 | 0.81 | TPSAB1 (0.46) | MAPK14CACNA1BALDH1A1 | |
| SCHEMBL2282080 | 0.81 | EPHX1 (0.43) | PSMB5MAPK14CACNA1BEPHX1PSMB8 | |
| SCHEMBL2286208 | 0.79 | EPHX1 (0.47) | PSMB5EPHX1PSMB8ALDH1A1MEN1 | |
| SCHEMBL1491533 | 0.78 | HDAC1 (0.47) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | disclosed |
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | PSMB5 580/4885MAPK14 654/4885CACNA1B 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.